source
- FDA grants accelerated approval for Rybrevant Faspro in recurrent/metastatic head and neck cancerThe U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carci…
- Novartis reports seven new tumor cases in children treated with Zolgensma gene therapyNovartis has disclosed that seven children who received its SMA gene therapy, Zolgensma, have been found to have tumors that were not previously reported. The cases were brought to light by an adv…